

## Supporting Information

### **A Water-Bridged H-Bonding Network Contributes to the Catalysis of the SAM-Dependent C-Methyltransferase HcgC**

*Liping Bai<sup>+</sup>, Tristan Wagner<sup>+</sup>, Tao Xu, Xile Hu, Ulrich Ermler, and Seigo Shima\**

anie\_201705605\_sm\_miscellaneous\_information.pdf

## Supporting Information

<b>Materials and methods</b> .....	2-10
<b>Figure S1.</b> Active site of the four monomers in the HcgC homotetramer.....	11
<b>Figure S2.</b> The linear compound found in one of the active site of the tetrameric HcgC.....	12
<b>Figure S3.</b> Active site structure of HcgC from <i>M. maripaludis</i> in complex with SAH and pyridinol <b>2</b> .....	13
<b>Figure S4.</b> Comparison of primary structure of HcgC.....	14
<b>Figure S5.</b> The active-site structure of HcgC crystallized in the presence of SAM and <b>2</b> .....	16
<b>Figure S6.</b> Kinetic data of the wild-type and mutated enzyme.....	17
<b>Table 1.</b> Statistics of the crystal structure analysis.....	18
<b>References for Supplementary information</b> .....	19

## Materials and methods

### Materials

*S*-(5'-adenosyl)-L-methionine (SAM) chloride dihydrochloride and *S*-(5'-adenosyl)-L-homocysteine (SAH) were purchased from Sigma-Aldrich. Sodium chloride, potassium chloride, potassium hydroxide, magnesium chloride, hydrogen chloride, Tris (hydroxymethyl) aminomethane, methanol, ethanol, kanamycin, 3-(*N*-morpholino)propanesulfonic acid (MOPS), 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) were obtained from Roth. Isopropyl  $\beta$ -D-thiogalactopyranoside (IPTG) was from Thermo. Pyridinol substrate **2** was chemically synthesized.<sup>[1]</sup>

### Construction of the expression vector for HcgC production

The *hcgC* gene from *Methanococcus maripaludis* strain S2 (MMP1498, GenBank accession number NP\_988618.1) was used for heterologous production of HcgC in this work. The *hcgC* gene was designed and synthesized by Genscript to optimize the codon usage and mRNA structure for expression in *Escherichia coli* and to have C-terminal extension with His-tag. The synthesized gene was inserted between the *Nde*I and *Sal*I sites of pET-24b(+). The *hcgC* sequences are shown below. The start codon is marked with yellow background. The *Nde*I and *Sal*I recognition sites are indicated with underline and double-underline, respectively. The codon for the mutation in the enzyme variants is indicated with light-blue background.

### The wild type HcgC:

CATATGAACTACGGCATTACCGAAAGCGTGAAAACGACCCGCAGCAAAATCAAA  
ATCAAAGATATTGTGTCCGATGTGGTGGAAGAAAGCGAACGCCATCAAATAT  
TTTCTGGAAGGCGAAGAATTTAAACAGGCAATTGTGTTTGGCGCTTACCTGTCAG

GTTCGTATATCGCGTACTCACTGCTGAAAGATTGCGAAGAAGTCATTATCGTGGA  
CATTAGCCGCATCTGAAAGATATTCTGTTCAACGACGGTATCAAATTCATGGAT  
CTGAACAAACTGCAACTGGAAGTGCCTAACGGCACCAGCATCAATCCGGATCTG  
GTGATTGACCTGACGGGTATCGGCGGTGTTAGTCCGGATCTGATTTCCTAAATTCA  
ATCCGAAAGTTCTGATCGTCGAAGATCCGAAAGGCAACCACGACAAAGGTATCT  
CTAAAATCGATAACACCGACAAACGTCTGTGCGTGGGCGCGAAAAAAGGTGTTT  
TGAAAACCTATCGCAGCTCTAAATTTAGCAAAACGTCTGGCACCATGACCCTGGT  
GGTGGATATTATCATGGACTCATGTGCGGAAATTAACGAACTGGATTTCGGTTCTG  
TATACCATCCCGAATCTGAAATACTTTGAGGGTACGGTCTTCCATGAGAAAAACG  
TGAAAAAATTCCTGACCGAACTGAATATGTCCGCCATTACCGTTAGTTCCATCGA  
TCACGTGGAATACGAACTGGAAGAAATCCTGTCAAAAAACATCAGCCGTGTGGA  
CTCGTTTCGTGAAAGAATTTGTCGAC

**The T6V mutant of HcgC:**

CATATGAACTACGGCATTGTGGAAAGCGTGAAAACGACCCGCAGCAAAATCAAA  
ATCAAAGATATTGTGTCCGATGTGGTGGAAAAGAAAGCGAACGCCATCAAATAT  
TTTCTGGAAGGCGAAGAATTTAAACAGGCAATTGTGTTTGGCGCTTACCTGTCAG  
GTTCGTATATCGCGTACTCACTGCTGAAAGATTGCGAAGAAGTCATTATCGTGGA  
CATTAGCCGCATCTGAAAGATATTCTGTTCAACGACGGTATCAAATTCATGGAT  
CTGAACAAACTGCAACTGGAAGTGCCTAACGGCACCAGCATCAATCCGGATCTG  
GTGATTGACCTGACGGGTATCGGCGGTGTTAGTCCGGATCTGATTTCCTAAATTCA  
ATCCGAAAGTTCTGATCGTCGAAGATCCGAAAGGCAACCACGACAAAGGTATCT  
CTAAAATCGATAACACCGACAAACGTCTGTGCGTGGGCGCGAAAAAAGGTGTTT  
TGAAAACCTATCGCAGCTCTAAATTTAGCAAAACGTCTGGCACCATGACCCTGGT  
GGTGGATATTATCATGGACTCATGTGCGGAAATTAACGAACTGGATTTCGGTTCTG

TATACCATCCCGAATCTGAAATACTTTGAGGGTACGGTCTTCCATGAGAAAAACG  
TGAAAAAATTCCTGACCGAACTGAATATGTCCGCCATTACCGTTAGTTCCATCGA  
TCACGTCGAATACGAACTGGAAGAAATCCTGTCAAAAAACATCAGCCGTGTGGA  
CTCGTTCGTGAAAGAATTTGTCGAC

**The Y51F mutant of HcgC:**

CAT**ATG**AACTACGGCATTACCGAAAGCGTGAAAACGACCCGCAGCAAAATCAAA  
ATCAAAGATATTGTGTCCGATGTGGTGGAAGAAAGCGAACGCCATCAAATAT  
TTTCTGGAAGGCGAAGAATTTAAACAGGCAATTGTGTTTGGCGCT**TTT**CTGTCAG  
GTTCGTATATCGCGTACTCACTGCTGAAAGATTGCGAAGAAGTCATTATCGTGGA  
CATTCAGCCGCATCTGAAAGATATTCTGTTCAACGACGGTATCAAATTCATGGAT  
CTGAACAAACTGCAACTGGAAGTACGGTAAACGGCACCAGCATCAATCCGGATCTG  
GTGATTGACCTGACGGGTATCGGCGGTGTTAGTCCGGATCTGATTTCCAAATTCA  
ATCCGAAAGTTCTGATCGTCGAAGATCCGAAAGGCAACCACGACAAAGGTATCT  
CTAAAATCGATAACACCGACAAACGTCTGTGCGTGGGCGCGAAAAAAGGTGTTC  
TGAAAACCTATCGCAGCTCTAAATTTAGCAAAACGTCTGGCACCATGACCCTGGT  
GGTGGATATTATCATGGACTCATGTCGCGAAATTAACGAACTGGATTTCGGTTCTG  
TATACCATCCCGAATCTGAAATACTTTGAGGGTACGGTCTTCCATGAGAAAAACG  
TGAAAAAATTCCTGACCGAACTGAATATGTCCGCCATTACCGTTAGTTCCATCGA  
TCACGTCGAATACGAACTGGAAGAAATCCTGTCAAAAAACATCAGCCGTGTGGA  
CTCGTTCGTGAAAGAATTTGTCGAC

**The S175A mutant of HcgC:**

CAT**ATG**AACTACGGCATTACCGAAAGCGTGAAAACGACCCGCAGCAAAATCAAA  
ATCAAAGATATTGTGTCCGATGTGGTGGAAGAAAGCGAACGCCATCAAATAT

TTTCTGGAAGGCGAAGAATTTAAACAGGCAATTGTGTTTGGCGCTTACCTGTCAG  
GTTCGTATATCGCGTACTCACTGCTGAAAGATTGCGAAGAAGTCATTATCGTGGA  
CATTCAGCCGCATCTGAAAGATATTCTGTTCAACGACGGTATCAAATTCATGGAT  
CTGAACAAACTGCAACTGGAAGTACGCGTAACGGCACCAGCATCAATCCGGATCTG  
GTGATTGACCTGACGGGTATCGGCGGTGTTAGTCCGGATCTGATTTCCAAATTCA  
ATCCGAAAGTTCTGATCGTCGAAGATCCGAAAGGCAACCACGACAAAGGTATCT  
CTAAAATCGATAACACCGACAAACGTCTGTGCGTGGGCGCGAAAAAAGGTGTTC  
TGAAAACCTATCGCAGCTCTAAATTTAGCAAAACGCGCGGCACCATGACCCTGGT  
GGTGGATATTATCATGGACTCATGTGCGGAAATTAACGAACTGGATTTCGGTTCTG  
TATACCATCCCGAATCTGAAATACTTTGAGGGTACGGTCTTCCATGAGAAAAACG  
TGAAAAAATTCCTGACCGAACTGAATATGTCCGCCATTACCGTTAGTTCCATCGA  
TCACGTGGAATACGAACTGGAAGAAATCCTGTCAAAAAACATCAGCCGTGTGGA  
CTCGTTCGTGAAAGAATTTGTCGAC

**The T179V mutant of HcgC:**

CATATGAACTACGGCATTACCGAAAGCGTGAAAACGACCCGCAGCAAAATCAAA  
ATCAAAGATATTGTGTCCGATGTGGTGGAAAAGAAAGCGAACGCCATCAAATAT  
TTTCTGGAAGGCGAAGAATTTAAACAGGCAATTGTGTTTGGCGCTTACCTGTCAG  
GTTCGTATATCGCGTACTCACTGCTGAAAGATTGCGAAGAAGTCATTATCGTGGA  
CATTCAGCCGCATCTGAAAGATATTCTGTTCAACGACGGTATCAAATTCATGGAT  
CTGAACAAACTGCAACTGGAAGTACGCGTAACGGCACCAGCATCAATCCGGATCTG  
GTGATTGACCTGACGGGTATCGGCGGTGTTAGTCCGGATCTGATTTCCAAATTCA  
ATCCGAAAGTTCTGATCGTCGAAGATCCGAAAGGCAACCACGACAAAGGTATCT  
CTAAAATCGATAACACCGACAAACGTCTGTGCGTGGGCGCGAAAAAAGGTGTTC  
TGAAAACCTATCGCAGCTCTAAATTTAGCAAAACGTCTGGCACCATGCTCCTGGT

GGTGGATATTATCATGGACTCATGTCGCGAAATTAACGAACTGGATTTCGGTTCTG  
TATACCATCCCGAATCTGAAATACTTTGAGGGTACGGTCTTCCATGAGAAAAACG  
TGAAAAAATTCCTGACCGAACTGAATATGTCCGCCATTACCGTTAGTTCCATCGA  
TCACGTCGAATACGAACTGGAAGAAATCCTGTCAAAAAACATCAGCCGTGTGGA  
CTCGTTCGTGAAAGAATTTGTTCGAC

**The E209Q mutant of HcgC:**

CATATGAACTACGGCATTACCGAAAGCGTGAAAACGACCCGCAGCAAAATCAAA  
ATCAAAGATATTGTGTCCGATGTGGTGGAAGAAAGCGAACGCCATCAAATAT  
TTTCTGGAAGGCGAAGAATTTAAACAGGCAATTGTGTTTGGCGCTTACCTGTCAG  
GTTCGTATATCGCGTACTCACTGCTGAAAGATTGCGAAGAAGTCATTATCGTGGA  
CATTACGCCGCATCTGAAAGATATTCTGTTCAACGACGGTATCAAATTCATGGAT  
CTGAACAAACTGCAACTGGAAGTACGGCACCAGCATCAATCCGGATCTG  
GTGATTGACCTGACGGGTATCGGCGGTGTTAGTCCGGATCTGATTTCCAAATTCA  
ATCCGAAAGTTCTGATCGTCGAAGATCCGAAAGGCAACCACGACAAAGGTATCT  
CTAAAATCGATAACACCGACAAACGTCTGTGCGTGGGCGCGAAAAAAGGTGTTC  
TGAAAACCTATCGCAGCTCTAAATTTAGCAAAACGTCTGGCACCATGACCCTGGT  
GGTGGATATTATCATGGACTCATGTCGCGAAATTAACGAACTGGATTTCGGTTCTG  
TATACCATCCCGAATCTGAAATACTTTCAGGGTACGGTCTTCCATGAGAAAAACG  
TGAAAAAATTCCTGACCGAACTGAATATGTCCGCCATTACCGTTAGTTCCATCGA  
TCACGTCGAATACGAACTGGAAGAAATCCTGTCAAAAAACATCAGCCGTGTGGA  
CTCGTTCGTGAAAGAATTTGTTCGAC

**The S233A mutant of HcgC:**

CATATGAACTACGGCATTACCGAAAGCGTGAAAACGACCCGCAGCAAAATCAAA  
ATCAAAGATATTGTGTCCGATGTGGTGGAAAAGAAAGCGAACGCCATCAAATAT  
TTTCTGGAAGGCGAAGAATTTAAACAGGCAATTGTGTTTGGCGCTTACCTGTCAG  
GTTTCGTATATCGCGTACTCACTGCTGAAAGATTGCGAAGAAGTCATTATCGTGGA  
CATTCAGCCGCATCTGAAAGATATTCTGTTCAACGACGGTATCAAATTCATGGAT  
CTGAACAAACTGCAACTGGAAGTACGTAACGGCACCAGCATCAATCCGGATCTG  
GTGATTGACCTGACGGGTATCGGCGGTGTTAGTCCGGATCTGATTTCCAAATTCA  
ATCCGAAAGTTCTGATCGTCGAAGATCCGAAAGGCAACCACGACAAAGGTATCT  
CTAAAATCGATAACACCGACAAACGTCTGTGCGTGGGCGCGAAAAAAGGTGTTT  
TGAAAACCTATCGCAGCTCTAAATTTAGCAAAACGTCTGGCACCATGACCCTGGT  
GGTGGATATTATCATGGACTCATGTGCGGAAATTAACGAACTGGATTTCGGTTCTG  
TATACCATCCCGAATCTGAAATACTTTGAGGGTACGGTCTTCCATGAGAAAAACG  
TGAAAAAATTCCTGACCGAACTGAATATGTCCGCCATTACCGTTCCGTCATCGA  
TCACGTCGAATACGAACTGGAAGAAATCCTGTCAAAAAACATCAGCCGTGTGGA  
CTCGTTCGTGAAAGAATTTGTCGAC

### Expression and purification

The HcgC expression vector pET24b(+) harboring the *hcgC* gene and its mutated genes were transferred into *E.coli* BL 21Star (DE3) strain (Invitrogen) and cultivated in LB medium at 37 °C with 50 µg/mL kanamycin. An over-night grown pre-culture (50 ml) was inoculated into 2-liter LB medium in 5-liter Erlenmeyer flask, which was stirred (500 rpm) using a stirrer bar. When OD<sub>600</sub> of the culture reached to 0.8-1.0, 1-mM IPTG (final concentration) was added to the medium to induce the production of the HcgC protein. After 4-6 hours cultivation at 37 °C, the *E. coli* cells were harvested by centrifugation at 15,000 ×g for 40 min at 4 °C. The harvested cells were stored at −75 °C before use. Protein purification was performed under the



aerobic condition. The frozen cell was suspended in the 45-mL of 50 mM Tris/HCl pH 7.0, 20 mM imidazole, 250 mM KCl (buffer A) and disrupted on ice by sonication (Bandelin, 200W) using KE76 tip with 70% power with 50% cycle for 1 min (10 times with 1 min intervals). The crude cell extract was centrifuged at  $18,000 \times g$  for 40 min at 4 °C. The supernatant was loaded onto a HisTrap HP column, which is packed with Ni Sepharose High Performance, equilibrated with buffer A. Target protein HcgC was eluted with linear gradient (0-100%) of 50 mM Tris/HCl pH 7.0 containing 250-mM NaCl and 500-mM imidazole (buffer B). The collected fractions were concentrated using ultrafilter (10 kDa cut-off filter, Millipore) to a final concentration of around 30 mg/mL and then stored at  $-75$  °C. Protein concentration was determined by the Bradford method using InstantBlue staining-solution from Expedeon. The mutated proteins were purified with the same method as the wild-type HcgC protein.

### **Enzyme activity assay**

The HcgC enzyme-reaction solution contained 10 mM MOPS/KOH pH 7.0, 1.0 mM SAM, variable concentrations of pyridinol **2** (0–0.2 mM) and 1.0  $\mu$ M HcgC or 1-10  $\mu$ M mutated enzyme. The enzyme reaction was performed aerobically under air at 37 °C. The reaction was started by addition of the enzyme solution. Product formed was determined using HPLC (JASCO) equipped with the Polar RP 80Å column (Phenomenex). The reaction solution (100  $\mu$ l) was filtrated using 0.2- $\mu$ m pore-size filter and 20  $\mu$ l was loaded to the column equilibrated with H<sub>2</sub>O (pH adjusted to 4.0 with HCl). Then, the column was washed with 2.5 ml H<sub>2</sub>O (pH 4.0) and then eluted with 0-100% methanol gradient in a 12.5 ml elution volume. The flow rate was 0.5 ml/min. The substrate and product were eluted at around 76% and 80% methanol, respectively. As the substrate **2** and product **3** have almost the same absorbance at 288 nm, the conversion rate from substrate to product was calculated from the ratio of [area of **3**] / [total area of **2** and **3**].<sup>[1]</sup>


## Crystallization

Crystallization of HcgC were performed under air. The buffer of HcgC was exchanged with 10 mM MOPS/KOH pH 7.0 by concentration-dilution cycles (three times) of the protein solution using 10-kDa cut filter and finally concentrated to ~5 mg/ml. The 96/24-well crystal plate, Combiclover Junior (Jena Bioscience), was used for crystallization. The drop consists of 1  $\mu$ l of enzyme solution containing ~5 mg/ml HcgC, 2 mM pyridinol **2** and 2 mM SAM or SAH and 1  $\mu$ l of the reservoir solution. The first hits were obtained in a reservoir solution containing 100 mM Tris/HCl pH 8.5, 40% polyethylene glycol (PEG) 400 and 200 mM lithium sulfate ( $\text{Li}_2\text{SO}_4$ ), and 100 mM HEPES/NaOH pH 7.5, 0.2 M NaCl, and 35% MPD (2-methyl-2,4-pentanediol) within several weeks. Co-crystals of HcgC with SAM and pyridinol came from a crystallization solution containing 50% v/v PEG 400, 100 mM Na acetate pH 4.5, 200 mM  $\text{Li}_2\text{SO}_4$ . HcgC cocrystallized with SAH and pyridinol came from a crystallization solution containing 40% v/v PEG 400, 100 mM Tris/HCl pH 8.5 and 200 mM  $\text{Li}_2\text{SO}_4$ . The freshly fished crystals (growth after 2 days) were obtained from the drops containing 2-mM SAH and 2-mM pyridinol in 100 mM HEPES/NaOH pH 7.0, 0.1 M NaCl, and 30% MPD. Crystals of the HcgC apoenzyme were obtained from a solution containing 100 mM HEPES/NaOH pH 7.5, 0.1 M NaCl, and 30% MPD. The apoenzyme crystals were soaked overnight in the crystallization solution, which contained 2 mM SAH and 3 mM pyridinol **2**.


## Structure analysis

The crystals were cryo-protected by soaking with 30 % glycerol (v/v) in the crystallization solution for 3-5 seconds. The diffraction experiments were performed at 100 K on beamline X10SA equipped with a PILATUS 6M detector at the Swiss Light Source (Villigen). The data were processed with XDS<sup>[2]</sup> and scaled with SCALA from the ccp4 suite.<sup>[3]</sup> The structure was


determined with PHASER<sup>[4]</sup> using the HcgC model from *Methanocaldococcus jannaschii* in complex with SAM (PDB code 2JJF) as a template. The molecular replacement calculation succeeded by using separately the N and C-terminal domain instead of the complete polypeptide chain. The model was manually constructed with COOT<sup>[5]</sup> and refined by PHENIX.<sup>[4]</sup> The final model was validated by using the MolProbity server (<http://molprobity.biochem.duke.edu>).<sup>[6]</sup> Data collection and refinement statistics of the model are listed in Table S2. The figures were generated and rendered with PyMOL (Version 1.5, Schrödinger, LLC).



**Figure S1.** Active sites of the four monomers in the HcgC homotetramer. (a) SAH and a linear compound, (b) SAH and **2**, (c) SAH and a mixture of **2** and a linear compound and (d) SAH.



**Figure S2.** The linear compound found in one of the active site of the tetrameric HcgC. The chemical structure was estimated from the structure of **2** and the interactions with amino acids. The  $2F_o-F_c$  map is contoured at  $1.5 \sigma$ .



**Figure S3.** Active site structure of HcgC from *M. maripaludis* in complex with SAH and pyridinol **2**. The four active sites of the dimer of homodimer (chain A-D) are shown in the panels. (a) Structure from “old” crystals containing SAH and pyridinol in solution (1.7 Å resolution). (b) Structure of the crystal freshly fished after two days within less than two days (2.0 Å resolution). (c) Structure of the HcgC-apoenzyme crystal soaked with the substrates (2.05 Å resolution).




[illegible][illegible][illegible]

[Methanococcus\_maripaludis]      0 0 0 0 0 0      β11  
    \*250      260


[Methanococcus_maripaludis]	T	S	K	N	T	S	R	V	D	S	F	V	K	E	F	.	.	.	.	.	.	
[Methanothermococcus_thermolithotrophicus]	I	W	K	N	T	S	R	I	N	S	F	V	E	K	I	K	.	.	.	.	.	
[Methanococcus_aeolicus]	L	L	K	N	I	D	R	I	Y	S	Y	V	E	K	I	K	.	.	.	.	.	
[Methanotorris_formicicus]	M	E	N	N	L	D	R	V	K	S	F	I	E	K	R	.	.	.	.	.	.	
[Methanocaldococcus_jannaschii]	L	S	N	N	I	N	L	I	Y	S	F	V	E	L	.	.	.	.	.	.	.	
[Methanothermobacter_thermautotrophicus]	L	E	R	N	L	S	M	T	K	S	R	V	I	P	A	D	L	F	K	.	.	
[Methanolacinia_paynteri]	I	D	N	N	L	K	K	I	N	S	T	I	L	D	F	R	G	D	Y	N	.	
[Methanobacterium_formicum]	M	E	E	Y	L	Q	K	I	D	S	V	V	A	D	V	S	I	.	.	.	.	.
[Methanothermus_fervidus]	I	E	K	F	I	K	K	I	K	S	K	V	I	E	I	K	.	.	.	.	.	
[Methanopyrus_kandleri]	I	G	E	V	L	D	E	I	L	F	E	I	R	E	R	.	.	.	.	.	.	
[Methanobrevibacter_smithii]	I	R	T	Q	L	D	R	I	E	S	K	M	I	.	.	.	.	.	.	.	.	
[Methanocorpusculum_labreanum]	L	R	E	S	L	I	R	I	D	E	I	E	V	E	T	D	D	R	C	.	.	
[Desulfurobacterium_sp._K6013]	L	N	D	I	L	R	E	I	Q	F	E	L	A	R	A	.	.	.	.	.	.	
[Desulfurobacterium_thermolithotrophum]	I	T	E	V	I	E	N	F	E	F	E	L	E	R	V	.	.	.	.	.	.	

**Figure S4.** Comparison of primary structures of HcgC.





**Figure S5.** The active-site structure of HcgC crystallized in the presence of SAM and **2**. In the crystallization drop, SAM and substrate **2** converted to SAH and the methylated product **3** by HcgC. Accordingly, HcgC is active under the crystallization conditions.



**Figure S6.** Kinetic data of the wild-type and mutated enzymes. The standard error of at least three measurements was calculated with the Standard Error Calculator. The assay mixture contained 1 mM SAM and variable concentrations of substrate **2**.

**Table 1.** Statistics of the crystal structure analysis.

	HcgC co-crystallized with SAM+pyridinol	HcgC co-crystallized with SAH+pyridinol	HcgC freshly co-crystallized with SAH+pyridinol	HcgC apo soaked with SAH+pyridinol
<b>Data collection</b>				
Wavelength (Å)	0.99999	0.99999	1.00001	1.00001
Space group	$P2_1$	$P2_1$	$P2_1$	$P2_1$
Resolution (Å)	50 – 1.75 (1.84 – 1.75)	50 – 1.70 (1.79 – 1.70)	50 – 2.10 (2.21 – 2.10)	50 – 2.05 (2.16 – 2.05)
Cell dimensions				
a, b, c (Å)	73.2, 77.7, 101.0	72.7, 83.0, 96.1	71.9, 83.5, 100.0	72.6, 81.0, 97.8
$\alpha, \beta, \gamma$ (°)	90.0, 110.9, 90.0	90.0, 108.0, 90.0	90.0, 109.5, 90.0	90.0, 108.2, 90.0
$R_{\text{merge}}$ (%) <sup>a</sup>	8.2 (64.6)	7.1 (56.2)	5.4 (54.4)	10.3 (71.7)
$R_{\text{pim}}$ (%) <sup>a</sup>	4.1 (33.1)	4.3 (33.4)	3.9 (41.2)	7.2 (49.8)
$CC_{1/2}$ <sup>a</sup>	99.7 (42.1)	99.7 (58.9)	99.8 (80.4)	99.3 (60.0)
$I/\sigma_I$ <sup>a</sup>	9.7 (2.2)	9.5 (2.1)	11.5 (1.7)	6.2 (1.4)
Completeness (%) <sup>a</sup>	99.7 (100.0)	99.6 (99.9)	97.9 (98.8)	96.7 (98.0)
Redundancy <sup>a</sup>	4.8 (4.7)	3.7 (3.8)	2.6 (2.5)	2.9 (2.9)
Number of unique reflections <sup>a</sup>	106203 (15490)	119006 (17367)	63739 (9372)	65248 (9601)
<b>Refinement</b>				
Resolution (Å)	50.0 – 1.75	50.0 – 1.70	50.0 – 2.10	30.0 – 2.05
Number of reflections	106177	118942	63705	65131
$R_{\text{work}}/R_{\text{free}}$ (%) <sup>b</sup>	16.7 / 19.3	15.9 / 19.2	20.2 / 23.3	19.7 / 23.6
Number of atoms				
Protein	8280	8359	8302	8263
Ligands/ions	200	205	208	212
Solvent	699	839	522	470
Mean B-value (Å <sup>2</sup> )	38.0	36.9	56.2	47.8
Molprobtity clash score, all atoms	1.3 (99 <sup>th</sup> percentile)	1.9 (99 <sup>th</sup> percentile)	0.7 (100 <sup>th</sup> percentile)	0.5 (100 <sup>th</sup> percentile)
Ramachandran plot				
Favored regions (%)	1025 (99.4)	1029 (98.9)	1035 (99.3)	1023 (98.6)
Outlier regions (%)	0	0	0	0
rmsd <sup>c</sup> bond lengths (Å)	0.010	0.005	0.010	0.010
rmsd <sup>c</sup> bond angles (°)	1.210	0.837	1.190	1.150
PDB code	5O4H	5O4J	5O4M	5O4N

<sup>a</sup> Values relative to the highest resolution shell are within parentheses. <sup>b</sup>  $R_{\text{free}}$  was calculated as the  $R_{\text{work}}$

for 5% of the reflections that were not included in the refinement. <sup>c</sup> rmsd, root mean square deviation.

## References for Supplementary information

- [1] T. Fujishiro, L. Bai, T. Xu, X. Xie, M. Schick, J. Kahnt, M. Rother, X. Hu, U. Ermler, S. Shima, *Angew. Chem. Int. Ed.* **2016**, *55*, 9648-9651.
- [2] W. Kabsch, *Acta Crystallogr. D* **2010**, *66*, 125-132.
- [3] M. D. Winn, C. C. Ballard, K. D. Cowtan, E. J. Dodson, P. Emsley, P. R. Evans, R. M. Keegan, E. B. Krissinel, A. G. W. Leslie, A. McCoy, S. J. McNicholas, G. N. Murshudov, N. S. Pannu, E. A. Potterton, H. R. Powell, R. J. Read, A. Vagin, K. S. Wilson, *Acta Crystallogr. D* **2011**, *67*, 235-242.
- [4] P. V. Afonine, R. W. Grosse-Kunstleve, V. B. Chen, J. J. Headd, N. W. Moriarty, J. S. Richardson, D. C. Richardson, A. Urzhumtsev, P. H. Zwart, P. D. Adams, *J. Appl. Crystallogr.* **2010**, *43*, 669-676.
- [5] P. Emsley, K. Cowtan, *Acta Crystallogr. D* **2004**, *60*, 2126-2132.
- [6] V. B. Chen, W. B. Arendall, J. J. Headd, D. A. Keedy, R. M. Immormino, G. J. Kapral, L. W. Murray, J. S. Richardson, D. C. Richardson, *Acta Crystallogr D* **2010**, *66*, 12-21.